Abstract: A disclosed wireless tunneling system tunnels communications between two processing apparatuses through a wireless link, while maintaining compliance of the communications between the two processing apparatuses with at least two different wired communication protocols. In one embodiment, the wireless tunneling system includes two wireless tunneling apparatuses that communicate with each other through the wireless link. A local wireless tunneling apparatus is coupled to a local processing apparatus through a wired connection and a remote wireless tunneling apparatus is coupled to the remote processing apparatus through another wired connection. The two processing apparatuses may communicate with each other through the wireless link using the two wireless tunneling apparatuses as if the two processing apparatuses were connected through wired connections.

Abstract: The present invention relates to a process for preparing 17?-acetoxy-6-methylenepregn-4-ene-3,20-dione (4) as an intermediate, and to processes for preparing medroxyprogesterone acetate (1) (17?-acetoxy-6?-methylpregn-4-ene-3,20-dione) and megestrol acetate (2) (17?-acetoxy-6-methylpregna-4,6-diene-3,20-dione) via this intermediate (4).

Abstract: 3-Oxyiminopregnane-21-carbolactones of formula I, wherein R is as defined by the specification, their production and use as pharmaceutical agents are described.

Abstract: This invention relates to (R)-(-)-methylphenyloxazolidinone derivatives, a process for their production and their use as pharmaceutical agents.

Abstract: Described are racemic and enantiomerically pure chiral phenyldihydrofuranones, their preparation and their use in drugs (selective inhibition of the cAMP-specific phosphodiesterase IV).

Abstract: Pharmaceutical preparations for the local treatment of inflammations are claimed herein, characterized in that they contain as the active ingredient one or two compounds of general Formula I ##STR1## wherein X is an oxygen atom or a methylene group,R.sub.1 and R.sub.2 represent a hydrogen atom or a hydrocarbon residue of maximally eight carbon atoms, optionally interrupted by an oxygen atom,R.sub.3 is a hydrogen atom or a hydrocarbon residue of maximally eight carbon atoms, optionally substituted by an oxo group, andR.sub.4 is a hydrogen atom or an alkyl group of maximally four carbon atoms.

Abstract: An agent for transdermal administration is described, which is characterized in that it contains gestodene esters with 1 to 20 carbon atoms in the ester radical optionally in combination with one or two estrogen(s).

Abstract: Pharmaceutical preparations for the local treatment of inflammations are claimed herein, characterized in that they contain as the active ingredient one or two compounds of general Formula I ##STR1## wherein X is an oxygen atom or a methylene group,R.sub.1 and R.sub.2 represent a hydrogen atom or a hydrocarbon residue of maximally eight carbon atoms, optionally interrupted by an oxygen atom,R.sub.3 is a hydrogen atom or a hydrocarbon residue of maximally eight carbon atoms, optionally substituted by an oxo group, andR.sub.4 is a hydrogen atom or an alkyl group of maximally four carbon atoms.

Abstract: Synthetically produced cephalostatin analogues of the formula I described in the disclosure, synthetic methods for preparing the cephalostatin analogues, pharmaceutical compositions containing the analogues and methods for using the analogues as active agent in pharmaceutical uses, particularly due to their cytotoxic activity.

Abstract: Glucocorticoids of general formula IR--Val--O--GC (II),are described,in whichO-GC is the radical of a 21-hydroxycorticoid that has an antiinflammatory action,Val represents a valine radical in the 21-position of the corticoid andR means a hydrogen atom or a hydrocarbon radical with up to 32 carbon atoms that is optionally substituted by hydroxy groups, amino groups, oxo groups and/or halogen atoms and/or interrupted by oxygen atoms, SO.sub.2 groups and/or NH groups and their salts.

Abstract: A 14.alpha.,17.alpha.-bridged estratriene of formula I ##STR1## wherein (a) OR.sup.3 is in .alpha.-positionR.sup.1, R.sup.2 and R.sup.3, each independently are (i) hydrogen, (ii) ##STR2## in which R.sup.4 is an organic radical with up to 11 carbon atoms or (iii) --(CH.sub.2).sub.n COOH wherein n=1-4, or (iv) R.sup.1 is a benzyl, C.sub.1 -C.sub.8 alkyl or C.sub.3 -C.sub.5 cycloalkyl, or(b) OR.sup.3 is in .beta.-positionR.sup.1, R.sup.2 and R.sup.3, each independently are (i) hydrogen, (ii) an acyl group with 1 to 12 carbon atoms or (iii) R.sup.1 is C.sub.1 -C.sub.8 alkyl, and in both (a) and (b) A--B is an etheno or ethano bridge.

Abstract: The new 14.alpha.,16.alpha.-ethano- and 14.alpha.,16.alpha.-etheno-estratrienes of general formula I, ##STR1## are described, in which A-B means a C-C single bond or C-C double bond,R.sub.1 means a hydrogen atom, a methyl or acyl group with 1-12 carbon atoms andX means oxygen or ##STR2## in which R.sub.2 represents a hydrogen atom or an acyl group with 1-12 carbon atoms,and a process for their production. The new compounds are very strong estrogens and are suitable for the production of pharmaceutical agents.

Abstract: A process for the production of 3-deoxy-4-ene steroids of the general formula I ##STR1## is described, in which R.sub.1, R.sub.2 and R.sub.3 mean a hydrogen atom or a methyl group,R.sub.4 represents a lower alkyl group, a phenyl group or a free, esterified or etherified hydroxy group,R.sub.5 symbolizes a hydrogen atom, a vinyl group or the grouping --C.tbd.CR.sub.6 with R.sub.6 meaning a hydrogen atom, an alkyl group with a maximum of 4 carbon atoms or a halogen atom,X represents a methylene group, a fluoromethylene group, an ethylidene group or a vinylidene group,Y and U represent a methylene group or an ethylidene group andZ symbolizes a methylene group, an ethylidene group, a vinylidene group, a chloromethylene group or a hydroxymethylene group and in which the bonds represent three single bonds or one double bond and two single bonds or a conjugated double bond.

Abstract: Androstane derivatives of the general Formula I ##STR1## in which R.sub.1 represents a hydrogen atom or a methyl group,X and Y each mean hydrogen atoms or together a carbon-carbon bond, andR.sub.2 symbolizes a hydrogen atom or an alkyl group with 1 to 6 carbon atoms,are pharmaceutically effective substances which have a distinct antiandrogenic effectiveness in topical application.

Abstract: Known pregnane derivatives are prepared by esterification of know androstane derivatives to give new esters of Formula III ##STR1## wherein in each case symbolizes a single bond or a double bond,n is 1 or 2,R.sub.1 is hydrogen or methyl,R.sub.2 is hydrogen or formyl, andR.sub.3 is chlorine, hydroxy or an alkanoyloxy group of up to 6 carbon atoms,and reaction of the latter with Ag(I) and formic acid.

Abstract: Estrane and androstane derivatives of formula I ##STR1## wherein X is bromine, iodine, triphenyltin or trialkyltin of 1 to 6 carbon atoms per alkyl radical,Y represents two hydrogen atoms or methylene,Z represents two hydrogen atoms, oxo or alkylenedioxy of 2 to 6 carbon atoms andV is ethylene, vinylene, 1,3-propylene or cyclopropylene,R.sub.1 is hydrogen or a hydrocarbon radical of up to 8 hydrocarbon atoms, optionally interrupted by an oxa group or substituted by an oxo group,R.sub.2 is methyl or ethyl,R.sub.3 and R.sub.4 represent a carbon-carbon bond or R.sub.3 is hydrogen and R.sub.4 is hydrogen or methyl,.DELTA.symbolizes a 4(5)-double bond if Z signifies two hydrogen atoms or an oxo group; or a 5(6)-double bond or, for the estrane derivatives of formula I, also a 5(10)-double bond, if Z is alkylenedioxy,are pharmacologically effective substances or intermediates for preparation thereof.

Abstract: A 3-methylene-4-androsten-17-one of formula I ##STR1## wherein R.sub.a represents a hydrogen atom or a saturated or unsaturated straight-chain or branched-chain, optionally substituted alkyl radical with 1-6 carbon atoms, in which R.sub.a is in the alpha- or beta-position, andR.sub.b represents a hydrogen atom, a hydroxyl or an --S(O).sub.n R.sub.c group, in which R.sub.c is a hydrogen atom or an alkyl or acyl group with 1-4 carbon atoms, n=0, 1 or 2, andX represents CH.sub.2, CHF, CHCl or CHBr, in which if R.sub.a is hydrogen and R.sub.b is hydroxyl or R.sub.a and R.sub.b each are hydrogen, X is not CH.sub.2.The new compounds of formula I are suitable for fertility control and for treatment of diseases which are promoted by estrogens.

Abstract: A process for the production of 17.alpha.-ethinyl-17.beta.-hydroxy-18-methyl-4,15-estradien-3-one is described comprising reacting a 17-enolester of formula II ##STR1## wherein R.sub.1 represents an alkyl radical with 1-3 carbon atoms andR.sub.2 represents an acyl or a trialkylsilyl group with 1-10 carbon atomsunder palladium catalysis, with compounds of formula II ##STR2## wherein R.sub.1 represents an alkyl radical with 1-3 carbon atoms, reducing the 17-keto group to the 17-hydroxy group in a manner known in the art, reducing the aromatic A-ring according to Birch, with liquid ammonia, to 3-methoxy-2,5(10),15-estratrien-17.beta.-ol, reoxidizing the 17-hydroxy group to the 17-keto group, ethinylating the 17-keto group and splitting off the 3-enolether to form 17.alpha.-ethinyl-17.beta.-hydroxy-18-methyl-4,15-estradiene-3-one.

Abstract: 6.alpha.-methylhydrocortisones of Formula I ##STR1## wherein R.sub.1 is alkanoyl of 2-6 carbon atoms or benzoyl andR.sub.2 is hydrogen or alkanoyl of 2-6 carbon atomshave valuable antiinflammatory properties.